209 related articles for article (PubMed ID: 26011393)
1. Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
Sakai N; Taguri M; Kobayashi K; Noguchi S; Ikeda S; Koh H; Satomi Y; Furuhata A
Int J Urol; 2015 Aug; 22(8):747-52. PubMed ID: 26011393
[TBL] [Abstract][Full Text] [Related]
2. Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening.
Tabei T; Taguri M; Sakai N; Koh H; Yosida M; Fujikawa A; Nirei T; Tsutsumi S; Ito H; Furuhata S; Kawahara T; Miyoshi Y; Noguchi S; Uemura H; Kobayashi K
Prostate; 2020 Aug; 80(11):824-830. PubMed ID: 32433780
[TBL] [Abstract][Full Text] [Related]
3. [Five-year results of prostate specific antigen (PSA) screening in Yokosuka City--comparative study between PSA-screened group and non-screened group].
Noguchi S; Satomi Y; Sakai N; Takemura H; Ikeda S; Okui N; Kobayashi M; Fukuoka H; Furuhata A
Hinyokika Kiyo; 2008 Mar; 54(3):197-201. PubMed ID: 18411775
[TBL] [Abstract][Full Text] [Related]
4. Editorial Comment from Dr Stamatiou to Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
Stamatiou KN
Int J Urol; 2015 Aug; 22(8):753. PubMed ID: 26011594
[No Abstract] [Full Text] [Related]
5. Editorial Comment from Dr Izumi to Clinical outcomes of prostate cancer patients in Yokosuka City, Japan: A comparative study between cases detected by prostate-specific antigen-based screening in Yokosuka and those detected by other means.
Izumi K
Int J Urol; 2015 Aug; 22(8):752-3. PubMed ID: 26011512
[No Abstract] [Full Text] [Related]
6. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
[TBL] [Abstract][Full Text] [Related]
7. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
8. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
Loeb S; Zhu X; Schroder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
[TBL] [Abstract][Full Text] [Related]
9. The effect of smoking on prostate cancer survival: a cohort analysis in Barcelona.
Murta-Nascimento C; Romero AI; Sala M; Lorente JA; Bellmunt J; Rodero NJ; Lloreta J; Hospital À; Burón A; Castells X; Macià F
Eur J Cancer Prev; 2015 Jul; 24(4):335-9. PubMed ID: 25075878
[TBL] [Abstract][Full Text] [Related]
10. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
12. NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.
Moul JW; Sarno MJ; McDermed JE; Triebell MT; Reynolds MA
Urology; 2014 Dec; 84(6):1427-32. PubMed ID: 25432832
[TBL] [Abstract][Full Text] [Related]
13. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
[TBL] [Abstract][Full Text] [Related]
14. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
15. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.
Neupane S; Steyerberg E; Raitanen J; Talala K; Pylväläinen J; Taari K; Tammela TL; Auvinen A
Int J Urol; 2018 Mar; 25(3):270-276. PubMed ID: 29224236
[TBL] [Abstract][Full Text] [Related]
17. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
[TBL] [Abstract][Full Text] [Related]
18. Salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy for prostate cancer: a single-center experience.
Yoshida T; Nakayama M; Suzuki O; Matsuzaki K; Kobayashi Y; Takeda K; Arai Y; Kakimoto K; Nishiyama K; Nishimura K
Jpn J Clin Oncol; 2011 Aug; 41(8):1031-6. PubMed ID: 21693484
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer Ki-67 (MIB-1) expression, perineural invasion, and gleason score as biopsy-based predictors of prostate cancer mortality: the Mayo model.
Tollefson MK; Karnes RJ; Kwon ED; Lohse CM; Rangel LJ; Mynderse LA; Cheville JC; Sebo TJ
Mayo Clin Proc; 2014 Mar; 89(3):308-18. PubMed ID: 24486077
[TBL] [Abstract][Full Text] [Related]
20. The prognostic significance of Gleason scores in metastatic prostate cancer.
Rusthoven CG; Carlson JA; Waxweiler TV; Yeh N; Raben D; Flaig TW; Kavanagh BD
Urol Oncol; 2014 Jul; 32(5):707-13. PubMed ID: 24629494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
